Researchers at MD Anderson Cancer Center have developed the first comprehensive framework to classify small-cell lung cancer into four unique subtypes, based on gene expression, and have identified potential therapeutic targets for each type.
On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
